EX-16.1 2 ex16-1.htm

 

Exhibit 16.1

 

 

August 16, 2021

 

Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

 

Commissioners:

 

We have read the statements made by Indaptus Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K/A of Indaptus Therapeutics, Inc. dated August 12, 2021. We agree with the statements concerning our Firm contained therein.

 

Very truly yours,

 

Tel-Aviv, Israel /s/ Kesselman & Kesselman
August 16, 2021 Certified Public Accountants (Isr.)
  A member firm of PricewaterhouseCoopers International Limited

 

Kesselman & Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103, Israel,

P.O Box 7187 Tel-Aviv 6107120, Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il